Previous 10 | Next 10 |
home / stock / rhhby / rhhby articles
Roche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer pat...
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and...
Thursday, Argenx SE (NASDAQ:ARGX) shares are trading higher in reaction to Chugai Pharmaceutical Co Ltd’s disappointing g...
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY). Under...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
Roche receives FDA clearance on its digital pathology solution for diagnostic use PR Newswire The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling patho...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a muc...